AU760213B2 - Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors - Google Patents

Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors Download PDF

Info

Publication number
AU760213B2
AU760213B2 AU35527/99A AU3552799A AU760213B2 AU 760213 B2 AU760213 B2 AU 760213B2 AU 35527/99 A AU35527/99 A AU 35527/99A AU 3552799 A AU3552799 A AU 3552799A AU 760213 B2 AU760213 B2 AU 760213B2
Authority
AU
Australia
Prior art keywords
aryl
heteroaryl
alkyl
alkoxy
clo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU35527/99A
Other languages
English (en)
Other versions
AU3552799A (en
Inventor
Brian Michael Andresen
Philip Dietrich Hammen
Joel Michael Hawkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU3552799A publication Critical patent/AU3552799A/en
Application granted granted Critical
Publication of AU760213B2 publication Critical patent/AU760213B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AU35527/99A 1998-04-10 1999-04-09 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors Ceased AU760213B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8131098P 1998-04-10 1998-04-10
US60/081310 1998-04-10
PCT/US1999/007858 WO1999052862A1 (en) 1998-04-10 1999-04-09 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
AU3552799A AU3552799A (en) 1999-11-01
AU760213B2 true AU760213B2 (en) 2003-05-08

Family

ID=22163376

Family Applications (2)

Application Number Title Priority Date Filing Date
AU35527/99A Ceased AU760213B2 (en) 1998-04-10 1999-04-09 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
AU23691/99A Ceased AU755004B2 (en) 1998-04-10 1999-04-09 Alkylated hindered sulfonamides and processes for their preparation by Michael addition to propiolates

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU23691/99A Ceased AU755004B2 (en) 1998-04-10 1999-04-09 Alkylated hindered sulfonamides and processes for their preparation by Michael addition to propiolates

Country Status (47)

Country Link
US (2) US6114568A (enExample)
EP (2) EP0949245B1 (enExample)
JP (2) JP3479511B2 (enExample)
KR (2) KR100357660B1 (enExample)
CN (3) CN1296474A (enExample)
AP (1) AP1095A (enExample)
AR (1) AR017731A1 (enExample)
AT (2) ATE206392T1 (enExample)
AU (2) AU760213B2 (enExample)
BG (1) BG63665B1 (enExample)
BR (2) BR9910110A (enExample)
CA (2) CA2268684C (enExample)
CO (1) CO4810299A1 (enExample)
DE (2) DE69900321T2 (enExample)
DK (1) DK0949245T3 (enExample)
DZ (1) DZ2754A1 (enExample)
EA (1) EA002277B1 (enExample)
EG (1) EG21985A (enExample)
ES (2) ES2163316T3 (enExample)
GT (1) GT199900047A (enExample)
HN (1) HN1999000043A (enExample)
HR (1) HRP990106B1 (enExample)
HU (2) HUP9901043A1 (enExample)
ID (2) ID23244A (enExample)
IL (2) IL129168A (enExample)
IN (1) IN192485B (enExample)
IS (1) IS5018A (enExample)
MA (1) MA24833A1 (enExample)
NO (1) NO991675L (enExample)
NZ (1) NZ335105A (enExample)
OA (1) OA11030A (enExample)
PA (1) PA8469601A1 (enExample)
PE (1) PE20000417A1 (enExample)
PL (2) PL332451A1 (enExample)
PT (1) PT949245E (enExample)
RU (1) RU2197479C2 (enExample)
SA (1) SA99200089A (enExample)
SG (1) SG75167A1 (enExample)
SK (1) SK45399A3 (enExample)
TN (1) TNSN99054A1 (enExample)
TR (2) TR199900756A2 (enExample)
TW (1) TW520354B (enExample)
UA (1) UA57039C2 (enExample)
UY (1) UY25469A1 (enExample)
WO (1) WO1999052862A1 (enExample)
YU (1) YU18399A (enExample)
ZA (2) ZA992627B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1134207A1 (en) * 2000-03-15 2001-09-19 Pfizer Products Inc. Process for preparing resorcinol derivatives
US6548667B2 (en) 2000-04-07 2003-04-15 Samsung Electronics Co. Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
US6844373B2 (en) * 2002-05-28 2005-01-18 Alcatel Composition comprising fluorinated, radiation-curable dyes for surface energy control
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
ITBO20050005U1 (it) * 2005-01-31 2006-08-01 Ali Spa Distributore di bevande ghiacciate e simili

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU523636A3 (ru) * 1973-06-18 1976-07-30 Стауффер Кемикал Компани (Фирма) Способ получени сульфоксидных или сульфоновых производных тиокарбаматов
ZA794723B (en) 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
GB9000725D0 (en) 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0922030A1 (en) * 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
DE69805473T2 (de) 1997-08-08 2003-01-16 Pfizer Products Inc., Groton Arylsulfonylaminohydroxamsäurederivate
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico

Also Published As

Publication number Publication date
JP2000026400A (ja) 2000-01-25
BG63665B1 (bg) 2002-08-30
DE69922638D1 (de) 2005-01-20
TR200002950T2 (tr) 2000-12-21
SK45399A3 (en) 2000-08-14
HN1999000043A (es) 1999-11-03
UY25469A1 (es) 1999-11-17
ATE206392T1 (de) 2001-10-15
HUP0101465A3 (en) 2002-11-28
AU2369199A (en) 1999-10-21
KR100357660B1 (ko) 2002-10-25
TR199900756A2 (xx) 1999-11-22
AU3552799A (en) 1999-11-01
JP3540959B2 (ja) 2004-07-07
HUP0101465A2 (hu) 2002-03-28
UA57039C2 (uk) 2003-06-16
IL138778A0 (en) 2001-10-31
PT949245E (pt) 2002-02-28
EA002277B1 (ru) 2002-02-28
NO991675L (no) 1999-10-11
EG21985A (en) 2002-05-31
NO991675D0 (no) 1999-04-09
KR19990082986A (ko) 1999-11-25
ATE284864T1 (de) 2005-01-15
EP0949245B1 (en) 2001-10-04
NZ335105A (en) 2000-03-27
YU18399A (sh) 2002-11-15
AR017731A1 (es) 2001-09-12
CA2268684C (en) 2004-07-13
US6114568A (en) 2000-09-05
DZ2754A1 (fr) 2003-09-15
DK0949245T3 (da) 2002-01-28
MA24833A1 (fr) 1999-12-31
EA199900277A3 (ru) 2000-04-24
EP1068180B1 (en) 2004-12-15
AP1095A (en) 2002-08-26
BG103320A (en) 2001-08-31
BR9902219A (pt) 2000-04-11
CA2327498C (en) 2006-01-31
IL129168A0 (en) 2000-02-17
DE69922638T2 (de) 2005-05-19
ID27208A (id) 2001-03-08
GT199900047A (es) 2000-09-15
EA199900277A2 (ru) 1999-10-28
DE69900321T2 (de) 2002-07-11
CN1288885A (zh) 2001-03-28
CN1296474A (zh) 2001-05-23
IN192485B (enExample) 2004-04-24
HRP990106B1 (en) 2003-08-31
JP2002511447A (ja) 2002-04-16
BR9910110A (pt) 2001-10-09
PE20000417A1 (es) 2000-05-24
PA8469601A1 (es) 2000-09-29
TNSN99054A1 (fr) 2005-11-10
SA99200089A (ar) 2005-12-03
PL332451A1 (en) 1999-10-11
AP9901506A0 (en) 1999-06-30
KR100377718B1 (ko) 2003-03-26
RU2197479C2 (ru) 2003-01-27
CA2327498A1 (en) 1999-10-21
CA2268684A1 (en) 1999-10-10
ZA200005370B (en) 2002-01-03
CO4810299A1 (es) 1999-06-30
SG75167A1 (en) 2000-09-19
HUP9901043A1 (hu) 2000-08-28
EP1068180A1 (en) 2001-01-17
CN1234396A (zh) 1999-11-10
ID23244A (id) 2000-03-30
EP0949245A1 (en) 1999-10-13
DE69900321D1 (de) 2001-11-08
IS5018A (is) 1999-10-11
PL343530A1 (en) 2001-08-27
OA11030A (en) 2002-02-07
US6229025B1 (en) 2001-05-08
JP3479511B2 (ja) 2003-12-15
KR20010042567A (ko) 2001-05-25
IL129168A (en) 2003-07-06
AU755004B2 (en) 2002-11-28
ES2163316T3 (es) 2002-01-16
HRP990106A2 (en) 1999-12-31
WO1999052862A1 (en) 1999-10-21
TW520354B (en) 2003-02-11
ES2234253T3 (es) 2005-06-16
HU9901043D0 (en) 1999-06-28
ZA992627B (en) 2000-10-09

Similar Documents

Publication Publication Date Title
RS59500B1 (sr) Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
EP1068180B1 (en) Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors
US6288246B1 (en) Process for preparing hydroxamic acids
CA2268679C (en) Process for preparing phenoxyphenylsulfonyl halides
MXPA00009903A (en) Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
CZ20003735A3 (cs) Způsob alkylace bráněných sulfonamidů vhodných k přípravě inhibitorů matricové metaloproteinasy
HK1023556A (en) Process for preparing phenoxyphenylsulfonyl halides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired